Catalyst Pharmaceuticals Inc CPRX
News
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
These small-cap stocks score highest when screened for quality
These small-cap stocks score highest when -2-
20 companies screened for quality in a cheap part of the stock market
20 companies screened for quality in a cheap -2-
20 companies screened for quality in a cheap part of the stock market
20 companies screened for quality in a cheap -2-
Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval